Could a cancer pill boost stem cell transplant success in AML?
NCT ID NCT06954987
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This phase II trial tests whether adding the drug venetoclax to standard chemotherapy and a stem cell transplant helps adults with acute myeloid leukemia (AML) stay in remission. About 244 participants will receive either venetoclax or a placebo before and after their transplant. The goal is to see if venetoclax can reduce the chance of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax
What this could lead to
If it works, this could improve the chance of staying cancer-free after a stem cell transplant for AML.
What could go wrong
This is an early phase II trial with only 244 participants, so results may not apply to everyone. Adding venetoclax may increase side effects like infections or organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.